REVIEWS  MONOCLONAL ANTIBODIES FOR DIAGNOSIS AND THERAP Y DECISION MAKING IN INFLAMMATION/INFECTION 

The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 December;54(6):582-98

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: English

Targeting NCA-95 and other granulocyte antigens and receptors with radiolabeled monoclonal antibodies (Mabs)

Meller J., Liersch T., Oezerden M. M., Sahlmann C. O., Meller B. ✉

¹ Department of Nuclear Medicine, University of Göttingen, Göttingen, Germany; ² Department of General and Visceral Surgery, University of Göttingen, Göttingen, Germany

During the last decade considerable effort has been made in the research for in vivo techniques of labeling neutrophils with peptides, labeled cytokines and 99mTc-labeled antigranulocyte monoclonal antibodies (AG-Mabs). In general the advantage of in vivo labeling is the simplicity of this approach compared with in vivo techniques. Three of these AG-Mabs have been evaluated in clinical studies: Besilesomab (Scintimun®), Sulesomab (Leucoscan®) and Fanolesomab (Leu-Tech®). White blood cells (WBCs) radiolabeled with AG-Mabs do not show the same behaviour as in vivo labeled white blood cells. Especially 99mTc-Sulesomab and 99mTc-Besilesomab image infectious foci mainly by non-specific extravasation with secondary binding to postmigratory leukocytes already present at the site of infection.